US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
The fightback begins: Boss of London's Queen Mary University tells pro
A university boss has been praised after telling a pro-Gaza student mob he will not meet them until2024-05-21China Issues White Paper on Community with Shared Future in Cyberspace
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Exchange Event Convened to Mark 8th Anniversary of Lancang
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Xi Stresses Striving in Unity to Fulfill Goals Set by Party Congress
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21‘The Blue Angels,’ filmed for IMAX, puts viewers in the ‘box’ with the elite flying squad
If you’re looking for a little bit of that “ Top Gun: Maverick ” spectacle and thrill at the movie t2024-05-21Xi Focus: Xi Calls for Scaling up Global Action on Wetlands Conservation As COP14 Opens
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment